Conmed Corp reports results on Wednesday 28 October, after the market closes.
Source: reported quarterly EPS and aggregated third-party estimates. Historical surprises are context, not a forecast.
View chart data
| Period | Reported EPS | Analysts' estimate |
|---|---|---|
| Sep '25 | $1.08 | $1.05 |
| Dec '25 | $1.43 | $1.32 |
| Mar '26 | $0.89 | $0.82 |
| Jun '26 | $1.38 | $1.11 |
What analysts expect
Analysts have been raising their forecasts going into the report. The average EPS estimate for the quarter is $1.00, in a range from $0.99 to $1.02, while the average revenue estimate stands at $336.3 million. For the full year, the analysts’ average EPS estimate is $4.54 based on 6 analysts, which would be down 1.2% on last year. That estimate has risen 4.6% over the past 90 days. Of the recommendations, 0 are positive, 6 neutral and 1 negative.
Company guidance
In its latest earnings release, management set Twelve Months Ending December 31, 2026 Adjusted Diluted EPS guidance at $4.48 to $4.60. In its latest earnings release, management also set Twelve Months Ending December 31, 2026 Net Sales (GAAP) guidance at $1.4 billion to $1.4 billion.
Earnings surprise model
The model estimates EPS could land above the analysts’ average estimate by 4.2%. Its estimated chance of an EPS beat is 75.0%, based on the last 4 quarters. The model shrinks the median recent surprise toward zero and uses a neutral prior for beat frequency; this small sample is a reference estimate, not company guidance.
Track record against estimates
The company reported EPS above the analysts’ average estimate in 4 of the last 4 quarters. Last quarter, EPS of $1.38 compared with an estimate of $1.11, exceeding it by 24.3%.
The trends going in
That growth rate was up 0.6 percentage points on the rate a quarter earlier. The trailing gross margin was 54.6%, while the trailing operating margin was 7.5%, down 7.9 percentage points from a year earlier. The trailing net margin was 3.4%. Net income over the twelve months was $47.1 million, which fell 64.5% on the year before.
Cash flow
Operating cash flow over the twelve months was $170.7 million, up 2.2% on the year before. Capital spending was $19.8 million, or 1.4% of revenue. Free cash flow, operating cash flow less capital spending, was $150.9 million, down 2.0% on the year before. Free cash flow was 11.0% of revenue (the free-cash-flow margin), down 0.8 percentage points from a year earlier. The average diluted share count fell 0.0% over the year.
How today compares
In the context of past results: today’s free-cash-flow margin of 11.0% is higher than 84% of the company’s own past quarterly readings, which have ranged from 0.6% to 12.9%. Today’s operating margin of 7.5% is higher than 44% of past readings (0.9% to 15.4%). Today’s twelve-month revenue growth rate of 5.2% is higher than 55% of past readings (−9.7% to 19.1%).
Questions this report will answer
Whether the pick-up in revenue growth continues. Whether results land above or below the analysts’ expectations set out above. Meanwhile, whether margins hold at the trailing levels above. The next filing will show whether the trends above continue, slow or reverse.
The valuation angle
Our model translates these figures into value. In our model, growth 5 percentage points lower would lower the value by 32.4%, and 5 percentage points higher would raise it by 42.3%. A free-cash-flow margin 1 percentage point lower would lower it by 10.1%.
